((Sara M. Tinsley, Ph.D., ARNP, AOCN))
It is important to differentiate between de novo AML and secondary AML because the treatment approach may differ.
We emphasize that waiting for test results is the right thing to do before beginning treatment in AML.
We may need to confirm an sAML diagnosis via the myeloid mutation panel to ensure that patients are receiving the right treatment for their AML type.
When deciding on treatment, we look at the patient’s performance status as well as their stability and fitness, but not so much their age, unless they are in their eighties.
We assess if they would be fit for chemo, which may still be possible, even at that age.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION